Trial Profile
Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms DasaHIT
- 09 May 2023 Status changed from active, no longer recruiting to completed.
- 28 Sep 2021 Planned End Date changed from 1 Dec 2022 to 1 Mar 2023.
- 28 Sep 2021 Planned primary completion date changed from 1 Dec 2022 to 1 Mar 2023.